Jean-Luc E Vanderheyden

age ~67

from Dousman, WI

Also known as:
  • Jean Luc Vanderheyden
  • Jean E Vanderheyden
  • Jean L Vanderheyden
  • Jeanluc E Vanderheyden
  • Jennifer S Vanderheyden
  • Luc Vanderheyden
  • Jeanluc Luc N
  • Jean N
  • Jean Luc Ernest
  • Jenny Vanderheyden
Phone and address:
375 Still Water Ct, Dousman, WI 53118
2624314132

Jean-Luc Vanderheyden Phones & Addresses

  • 375 Still Water Ct, Dousman, WI 53118 • 2624314132
  • Westborough, MA
  • Boston, MA
  • Saint Louis, MO
  • Seattle, WA
  • Chicago, IL
  • Waukesha, WI

Work

  • Company:
    Jlvmi consulting llc
    Feb 2012
  • Address:
    Greater Milwaukee Area
  • Position:
    Owner / executive consultant

Education

  • Degree:
    Ph.D.
  • School / High School:
    University of Cincinnati
    1980 to 1985
  • Specialities:
    Analytical Chemistry

Skills

Drug Development • Clinical Trials • R&D • Molecular Imaging • Technology Transfer • Chemistry • Fda • Gmp • Biomarkers • Cancer • Pharmacology • Protein Chemistry • Radiochemistry • Clinical Research • Assay Development • Medical Devices • Medical Imaging • Biotechnology • Lifesciences • Apoptosis • Commercialization • Sop • Analytical Chemistry • Formulation • Angiogenesis • Nuclear Medicine • Mri • Innovation Management • Translational Medicine • Toxicology • Pharmaceutical Industry • Pet • Oncology • Clinical Development • Life Sciences • Research and Development • Drug Discovery • Formulation Development

Languages

Dutch

Ranks

  • Certificate:
    European Association of Nuclear Medicine Radiopharmacy Certificate 2007

Industries

Pharmaceuticals

Resumes

Jean-Luc Vanderheyden Photo 1

Owner And Executive Consultant

view source
Location:
Dousman, WI
Industry:
Pharmaceuticals
Work:
JLVMI Consulting LLC - Greater Milwaukee Area since Feb 2012
Owner / Executive Consultant

GE Healthcare - Waukesha, WI Nov 2005 - Dec 2011
Global MI Scientist and Research Manager

University of Massachusetts 2002 - 2005
VIsiting Associate Professor, Nuclear Medicine/Radiology

Theseus Imaging/North American Scientific Inc. 2001 - 2005
VP of R&D

Covidien (Formerly Mallinckrodt Medical/TYCO Healthcare) 1991 - 2001
Director, US Nuclear Medicine R&D
Education:
University of Cincinnati 1980 - 1985
Ph.D., Analytical Chemistry
Université libre de Bruxelles 1975 - 1980
Skills:
Drug Development
Clinical Trials
R&D
Molecular Imaging
Technology Transfer
Chemistry
Fda
Gmp
Biomarkers
Cancer
Pharmacology
Protein Chemistry
Radiochemistry
Clinical Research
Assay Development
Medical Devices
Medical Imaging
Biotechnology
Lifesciences
Apoptosis
Commercialization
Sop
Analytical Chemistry
Formulation
Angiogenesis
Nuclear Medicine
Mri
Innovation Management
Translational Medicine
Toxicology
Pharmaceutical Industry
Pet
Oncology
Clinical Development
Life Sciences
Research and Development
Drug Discovery
Formulation Development
Languages:
Dutch
Certifications:
European Association of Nuclear Medicine Radiopharmacy Certificate 2007

Us Patents

  • Radionuclide Generator System And Method For Its Preparation And Use

    view source
  • US Patent:
    49907875, Feb 5, 1991
  • Filed:
    Sep 29, 1989
  • Appl. No.:
    7/416221
  • Inventors:
    Jean-Luc Vanderheyden - Seattle WA
    Fu-Min Su - Seattle WA
  • Assignee:
    NeoRx Corporation - Seattle WA
  • International Classification:
    C01G 4700
  • US Classification:
    250432PD
  • Abstract:
    Improved radionuclide generators include a substantially insoluble salt of a parent radionuclide precursor which may be directly irradiated and then packed in a column for subsequent elution of the daughter radionuclide without the production of counter ion isotopic contaminants. The parent radionuclide precursor is provided in the form of an insoluble salt of the parent element whose counter ion, preferably aluminum, forms a relatively soluble salt with the desired daughter radionuclide. The improved generators may be prepared by reacting a parent radionuclide precursor with aluminum to obtain an aluminum salt of the precursor having low solubility in water, irradiating the aluminum salt to obtain an irradiated aluminum salt of the parent radionuclide, and then disposing the irradiated parent radionuclide in an elutable container. Useful parent radionuclide precursors include molybdenum-98 in the form of molybdate for the production of daughter. sup. 99m Tc, as soluble pertechnetate, and tungsten-186 in the form of tungstate for the production of daughter. sup.
  • .Sup.99M Tc.sup.(Iii) Myocardial Imaging Agents Which Are Non-Reducable In Vivo

    view source
  • US Patent:
    47956267, Jan 3, 1989
  • Filed:
    Mar 11, 1988
  • Appl. No.:
    7/172969
  • Inventors:
    Edward A. Deutsch - Cincinnati OH
    Jean-Luc Vanderheyden - Seattle WA
  • Assignee:
    University of Cincinnati - Cincinnati OH
  • International Classification:
    A61K 4902
    C07F 1300
  • US Classification:
    424 11
  • Abstract:
    A cationic. sup. 99m Tc. sup. III myocardial imaging agent is disclosed which has a relatively negative redox potential. This prevents in vivo reduction of the Tc(III) to Tc(II). The redox potential of the Tc(III) is controlled by complexing the Tc with both hard and soft atoms. Preferably four of the atoms complexed to the Tc(III) are hard atoms such as nitrogen or oxygen and the remaining two are soft atoms such as phosphorous or arsenic. These imaging agents are particularly useful in imaging the human heart.
  • Metal-Radionuclide-Labeled Proteins And Glycoproteins For Diagnosis And Therapy

    view source
  • US Patent:
    56819277, Oct 28, 1997
  • Filed:
    Jun 11, 1993
  • Appl. No.:
    8/075305
  • Inventors:
    Alan R. Fritzberg - Edmonds WA
    Sudhakar Kasina - Kirkland WA
    Tripuraneni N. Rao - Mill Creek WA
    Jean-Luc VanderHeyden - Seattle WA
    Ananthachari Srinivasan - Kirkland WA
  • Assignee:
    NeoRx Corporation - Seattle WA
  • International Classification:
    C07K 508
    C07K 1706
    A61K 3944
    A61K 5110
  • US Classification:
    530331
  • Abstract:
    Chelated radionuclide compositions are provided for conjugation to polypeptides and carbohydrates. The resulting conjugates may be used in diagnosis and therapy.
  • Method Of Isolating Radioactive Perrhenate Or Pertechnetate From An Aqueous Solution

    view source
  • US Patent:
    47786728, Oct 18, 1988
  • Filed:
    Nov 27, 1985
  • Appl. No.:
    6/802779
  • Inventors:
    Edward A. Deutsch - Cincinnati OH
    Jean-Luc Vanderheyden - Seattle WA
  • Assignee:
    University of Cincinnati - Cincinnati OH
  • International Classification:
    A61K 4300
    C01G 4700
    C01G 5700
  • US Classification:
    424 11
  • Abstract:
    Pure perihenate is isolated from a aqueous crude solution of perrhenate by first associating the perrherate with a lipophilic counter ion such as tetrabutyl ammonium. This is added to the solution in a form such as tetrabutyl ammonium bromide. Tetrabutyl ammonium perrhenate is formed. The aqueous mixture is then added to a reverse phase separation column such as a C. sub. 18 Sep Pak filter which has been previously loaded with the lipophilic counter ion. The aqueous portion of the crude mixture is eluted from the column with water. Subsequently the purified perrhenate associated with the lipophilic counter ion is removed with a less polar solvent such as ethanol. Pertechnetate can also be separated from an aqueous mixture in the same manner. These procedures are particularly suited for isolating relatively pure radioactive forms of perrhenate and pertechnetate such as Re. sup. 186 O. sub. 4. sup. -, Re. sup. 188 O. sub. 4. sup. -, and. sup. 99m TcO. sub. 4. sup. -.
  • Conjugates For Bone Imaging And Bone Cancer Therapy

    view source
  • US Patent:
    52021092, Apr 13, 1993
  • Filed:
    Jan 31, 1991
  • Appl. No.:
    7/643578
  • Inventors:
    Alan R. Fritzberg - Edmonds WA
    Jean-Luc E. Vanderheyden - Seattle WA
    Sudhakar Kasina - Kirkland WA
    Jeffrey N. Fitzner - Seattle WA
  • Assignee:
    NeoRx Corporation - Seattle WA
  • International Classification:
    A61K 4902
  • US Classification:
    424 11
  • Abstract:
    The present invention provides conjugates formed from calcified tissues targeting agents and radiolabeled compounds. One such conjugate comprises a chelate and a targeting agent that is capable of associating with calcified tissue, wherein the chelate contains at least one nitrogen atom or at least one sulfur atom or combinations thereof as the donor atoms. Another aspect of the invention provides method for using the conjugates for diagnostic and therapeutic purposes, including those related to bone cancer.
  • Metal-Radionuclide-Labeled Proteins And Glycoproteins For Diagnosis And Therapy

    view source
  • US Patent:
    56166923, Apr 1, 1997
  • Filed:
    May 8, 1995
  • Appl. No.:
    8/436961
  • Inventors:
    Alan R. Fritzberg - Edmonds WA
    Sudhakar Kasina - Kirkland WA
    Tripuraneni N. Rao - Mill Creek WA
    Jean-Luc VanderHeyden - Seattle WA
    Ananthachari Srinivasan - Kirkland WA
  • Assignee:
    NeoRx Corporation - Seattle WA
  • International Classification:
    C07K 508
    C07K 1700
    A61K 39385
    A61K 5110
  • US Classification:
    5303915
  • Abstract:
    Chelated radionuclide compositions are provided for conjugation to polypeptides and carbohydrates. The resulting conjugates may be used in diagnosis and therapy.
  • Stable Therapeutic Radionuclide Compositions And Methods For Preparation Thereof

    view source
  • US Patent:
    53935128, Feb 28, 1995
  • Filed:
    Sep 20, 1993
  • Appl. No.:
    8/124359
  • Inventors:
    Jean-Luc Vanderheyden - Seattle WA
    Alan R. Fritzberg - Edmonds WA
    Joseph E. Bugaj - Bothell WA
    Fu-Min Su - Seattle WA
    Prasanna Venkatesan - Kirkland WA
  • International Classification:
    A61K 4300
    A61K 4902
  • US Classification:
    424 153
  • Abstract:
    Stable therapeutic radionuclide compositions comprising, for example,. sup. 186 Re,. sup. 188 Re and. sup. 131 I stably bound to a proteinaceous targeting moiety and suitable for human in vivo administration are disclosed. Stabilizing agents preferably comprise antioxidants and challenging agents, and combination of HSA with an antioxidant and/or challenging agent provides enhanced long term stability. Ascorbic acid is an especially preferred stabilizing agent, which provides stability of therapeutic radionuclide compositions at levels of at least about 90% for several hours up to several days.
  • Conjugates For Bone Imaging And Bone Cancer Therapy

    view source
  • US Patent:
    50892495, Feb 18, 1992
  • Filed:
    Jun 16, 1988
  • Appl. No.:
    7/207686
  • Inventors:
    Alan R. Fritzberg - Edmonds WA
    Jean-Luc E. Vanderheyden - Seattle WA
    Sudhakar Kasina - Kirkland WA
    Jeffrey N. Fitzner - Seattle WA
  • Assignee:
    NeoRx Corporation - Seattle WA
  • International Classification:
    A61K 4902
    C07F 1300
  • US Classification:
    424 11
  • Abstract:
    The present invention provides conjugates formed from calcified tissues targeting agents and radiolabeled compounds. One such conjugate comprises a chelate and a targeting agent that is capable of associating with calcified tissue, wherein the chelate contains at least one nitrogen atom or at least one sulfur atom or combinations thereof as the donor atoms. Another aspect of the invention provides methods for using the conjugates for diagnostic and therapeutic purposes, including those related to bone cancer.

Get Report for Jean-Luc E Vanderheyden from Dousman, WI, age ~67
Control profile